Lokivetmab

Lokivetmab is a monoclonal antibody used to treat allergic dermatitis and atopic dermatitis in dogs. It targets the cytokine interleukin-31 (IL-31), which plays a key role in itch and inflammation. Read more

Lokivetmab is a monoclonal antibody used to treat allergic dermatitis and atopic dermatitis in dogs. It targets the cytokine interleukin-31 (IL-31), which plays a key role in itch and inflammation.

Essential insights

• Inhibition of IL-31: Lokivetmab specifically binds to IL-31, preventing its interaction with cell surface receptors. This reduces signaling responsible for itch and inflammation.
• Reduction of Itch and Inflammation: By neutralizing IL-31, Lokivetmab rapidly alleviates itch and promotes healing of skin damage caused by chronic itching.
• High Specificity: Lokivetmab is specifically designed to target canine IL-31 with minimal effects on other molecules or processes, reducing the risk of side effects.